Back to top
more

Omeros (OMER)

(Real Time Quote from BATS)

$3.30 USD

3.30
1,104,476

-0.87 (-20.86%)

Updated May 16, 2024 03:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Products

Better trading starts here.

Brokerage Reports

Research for OMER

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Omeros Corporation [OMER]

Reports for Purchase

Showing records 301 - 320 ( 423 total )

Company: Omeros Corporation

Industry: Medical - Products

Record: 301

05/14/2013

Company Report

Pages: 8

Q1 Financials In-Line; We Project Financing Extends Runway Into Q4.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 302

05/03/2013

Daily Note

Pages: 6

In Addition To aHUS, OMS721 Could Become A Subcutaneous Treatment For AMD. We See Potential For Clinical Trials In 2014. Reiterate OUTPERFORM & $20 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 303

05/01/2013

Daily Note

Pages: 6

Applied For Fast Track Designation For OMS824 In Huntington''s

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 304

04/17/2013

Daily Note

Pages: 6

Applies For Orphan Drug Designation For OMS721 In aHUS; We Believe OMS721 Has Best-In-Class Potential; Reiterate OUTPERFORM And $20 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 305

04/15/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 15

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 306

04/10/2013

Daily Note

Pages: 6

Preclinical Data Suggests Omeros'' GPR17 Antagonists May Reverse Multiple Sclerosis Degeneration; Reiterate OUTPERFORM and $20 FV.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 307

03/26/2013

Daily Note

Pages: 7

OMS824 Phase 1 Suggests Potency And Predictable Dosing For A Potential Blockbuster; Reiterate OUTPERFORM and $20 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 308

03/19/2013

Daily Note

Pages: 7

With Newly Defined MOA, PDE7 Inhibitor Set to Enter the Clinic in H2:13; Reiterate OUTPERFORM and $20 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 309

03/18/2013

Company Report

Pages: 8

Q4 Financials a Non-Event; Next - Phase 1 Data for OMS824 in Schizophrenia; Reiterate OUTPERFORM and $20 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 310

03/04/2013

Industry Report

Pages: 32

Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 311

03/03/2013

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of March 4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 312

02/08/2013

Daily Note

Pages: 7

Pipeline Progression: MASP-2 Inhibitor OMS721 Heading For The Clinic In 2013

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 313

02/04/2013

Industry Report

Pages: 22

February and 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 314

01/22/2013

Daily Note

Pages: 6

90-Day Results Fortify OMS302 Safety

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 315

01/16/2013

Daily Note

Pages: 8

GPCR Program Unlocks Class B Targets To Provide Small Molecule Treatments For Oncology; Reiterate OUTPERFORM and $20 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 316

01/03/2013

Industry Report

Pages: 22

January and 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 317

12/27/2012

Daily Note

Pages: 8

We Recommend Buying OMER On Weakness As Mixed OMS103HP Phase 3 Results Still Warrant Continued Development

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 318

12/06/2012

Company Report

Pages: 6

Phase 1 OMS824, a PDE10 inhibitor, Data Supports Continued Development; Reiterate OUTPERFORM and $20 Fair Value.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 319

11/14/2012

Daily Note

Pages: 7

Buy OMER; With Strengthening Fundamentals- Weakness Is Irrational, In Our View; We See Compelling Risk:Reward In Front Of Near- Term OMS103HP Ph3 Results

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 320

11/12/2012

Company Report

Pages: 8

Q3 Financials a Non-Event; We See Buying Opportunity In Front Of OMS103HP Phase 3 Data by Year-end; Reiterate OUTPERFORM and $20 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party